Researchers have defined a new genetic disease caused by a mutation in the IVNS1ABP gene. The condition marks a rare combination of premature physical aging and progressive neurological decline caused ...
BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.
Researchers reported at the 2026 European Lung Cancer Congress that Hernexeos (zongertinib) led to high response rates and disease control in patients with advanced HER2-mutant no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results